27 products total
(w/ the additional products distributed in Mexico).
Big Pharma is looking @ the IPs . - the patents , and maybe a future publication in a journal that the oncology community reads.
it requires patience on a different level for shareholders , as the community hurdle is there also.
We are in that waiting period longs . i hope you all will understand the hurdles in Bio-Tech .
We're not @ level 1.0
SEC filings current ,
clinical trials and FDA approval,
but we are @ 3.0
, and now waiting on approval by the oncology community . These are the people that decide which treatments get used - along with the insurers .
NanoStilbene could lower the overall insurance cost if used in combination w/ chemotherapy,
and various immunotherapies .
It has to be published first for the oncology community to notice it
Here is the TSOI PR that mentions this : http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80602113/therapeutic-solutions-international-announces-posi August 26, 2019
TSOI) announced today positive results from a pilot clinical trial in advanced cancer patients which have been submitted as a scientific manuscript to a peer reviewed medical journal.
it will get very interesting from here on out ;)
publication & cred from the R and D side of TSOI